Show simple item record

dc.contributor.authorHorsch, D
dc.contributor.authorAnthony, L
dc.contributor.authorGross, D
dc.contributor.authorValle, Juan W
dc.contributor.authorWelins, S
dc.contributor.authorBenavent, M
dc.contributor.authorKassler-Taub, K
dc.contributor.authorBinder P
dc.contributor.authorBanks, P
dc.contributor.authorLapuerta, P
dc.contributor.authorKulke, M
dc.date.accessioned2020-06-15T12:57:38Z
dc.date.available2020-06-15T12:57:38Z
dc.date.issued2020en
dc.identifier.citationHorsch D, Anthony L, Gross D, Valle JW, Welins S, Benavent M, et al. The telepath phase 3 study: an analysis of long-term treatment with telotristat ethyl in patients with carcinoid syndrome symptoms. Pancreas. 2020;49(3):471-en
dc.identifier.urihttp://hdl.handle.net/10541/622967
dc.language.isoenen
dc.titleThe telepath phase 3 study: an analysis of long-term treatment with telotristat ethyl in patients with carcinoid syndrome symptomsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCenter for Neuroendocrine Tumors, Bad Berka, Germanyen
dc.identifier.journalPancreasen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record